Open AccessSafety and Feasibility of Achieving Lower Systolic Blood Pressure Goals in Persons With Type 2 Diabetes: The SANDS Trial
Author(s) -
Weir Matthew R.,
Yeh Fawn,
Silverman Angela,
Devereux Richard B.,
Galloway James M.,
Henderson Jeffrey A.,
Howard William J.,
Russell Marie,
Wilson Charlton,
Ratner Robert,
Sorkin John,
Umans Jason G.,
Fleg Jerome L.,
Stylianou Mario,
Lee Elisa,
Howard Barbara V.
Publication year - 2009
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/j.1751-7176.2009.00121.x
Subject(s) - medicine , type 2 diabetes , blood pressure , diabetes mellitus , lower blood pressure , cardiology , randomized controlled trial , physical therapy , endocrinology
The Stop Atherosclerosis in Native Diabetics Study (SANDS) was a randomized open‐label clinical trial in type 2 diabetics designed to examine the effects of intensive reduction of blood pressure, aggressive vs standard goals (≤115/75 mm Hg vs ≤130/80 mm Hg), and low‐density lipoprotein (LDL) cholesterol on the composite outcome of change in carotid intimal‐medial thickness and cardiovascular events. The study demonstrated that in conjunction with a lower LDL cholesterol target of 70 mg/dL, aggressive systolic blood pressure–lowering resulted in a reduction in carotid intimal‐medial thickness and left ventricular mass without measurable differences in cardiovascular events. The blood pressure treatment algorithm included renin‐angiotensin system blockade, with other agents added if necessary. The authors conclude that both standard and more aggressive systolic blood pressure reduction can be achieved with excellent safety and good tolerability in patients with type 2 diabetes mellitus.